Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors
- Resource Type
- article
- Authors
- Fen Yang; Huali Wu; Yunhai Bo; Ye Lu; Hong Pan; Su Li; Qin Lu; Simin Xie; Harry Liao; Bing Wang
- Source
- Frontiers in Pharmacology, Vol 12 (2022)
- Subject
- TQ-B3101
pediatric
pharmacokinetic
model
solid tumor
Therapeutics. Pharmacology
RM1-950
- Language
- English
- ISSN
- 1663-9812
Background: TQ-B3101 is a novel kinase inhibitor currently in development for the treatment of advanced malignant solid tumor and relapsed or refractory ALK-positive anaplastic large cell lymphoma.Methods: A population pharmacokinetic model was developed using data collected from a Phase 1 study and a Phase 2 study to characterize the pharmacokinetic of TQ-B3101 and its active metabolite (TQ-B3101M). The final model was used to optimize dosing of TQ-B3101 for pediatric patients (6-